I must apologize first for not blogging on Monday and Tuesday, but I was on a ski trip with the family and not thinking about the markets.  My alert for Monday (BLGW) is doing very well I’m happy to report.

I jumped back in to my research this morning and came across a great company that has solid prospects:  Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis:physiological process involving the growth of new blood vessels from pre-existing vessels).

GTF’s AutoloGel System utilizes a unique technology that enables rapid isolation and activation of platelet rich plasma (PRP) from a patient’s own blood. The PRP is subsequently processed to produce a gel for application to the wound bed, re-establishing a balance needed for natural healing to occur. AutoloGel contains growth factors, cytokines and chemokines that are essential for normal wound healing. The AutoloGel System is used at the point-of care and is the only PRP System indicated for use in exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds.  The AutoloGel System is the only PRP system that is FDA cleared for the care of wounds.

The company is generating revenues and those revenues are increasing significantly.  They have cash-in-the-bank and NO long term debt….always a positive sign for me.  With the 2009 capital raise, that bought the company some time to execute on their plan.  Based upon what I have seen, they have high expectations for their AutoloGel System.

The chart indicates that the stock is trading near the bottom of its most recent trading range.

• After a steep selloff, the stock might be ready to run again
• An Amex stock, GTF is trading at attractive levels
• The strongest support is at 40 cents (see the chart)…. I don’t think it will drop that far, but it could
  

I am recommending that traders put GTF on their radar screens.  I think the downside risk is low, but the upside is strong.

As always, do your own due diligence.

Good luck and good trading,

Jeffrey Dean

Editor